Is the European medical products authorization regulation equipped to cope with the challenges of nanomedicines?

Barbel R. Dorbeck-Jung, Nupur Chowdhury, Nupur Chowdhury

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)

Abstract

This article analyses the emerging European regulatory activities in relation to nanopharmaceuticals. The central question is whether the regulatory responses are appropriate to cope with the regulatory problems nanomedicinal development is posing. The article explores whether the medical product regulations are robust enough, whether there are certain regulatory gaps, and whether the competent bodies have the expertise to evaluate nanomedicinal products when approval is applied for. Based on a social-constructive approach, the article identifies significant regulatory actors, their ideas on regulatory problems, and preliminary governance responses to them. It finds that the current dynamic regulatory structure appears robust enough to adapt to some of the technological challenges posed by nanomedicines. It concludes that regulators have not yet responded adequately to regulatory gaps related to definitions, classification and specific safety, quality, and efficacy standards that nanopharmaceutical development seems to require. As a consequence of these deficiencies legal certainty, a principle of high priority in European medical regulation policy, cannot be sufficiently provided.
Original languageEnglish
Pages (from-to)276-303
JournalLaw & policy
Volume33
Issue number2
DOIs
Publication statusPublished - 2011

Fingerprint

authorization
regulation
expertise
governance

Keywords

  • METIS-271225
  • IR-78741

Cite this

Dorbeck-Jung, Barbel R. ; Chowdhury, Nupur ; Chowdhury, Nupur. / Is the European medical products authorization regulation equipped to cope with the challenges of nanomedicines?. In: Law & policy. 2011 ; Vol. 33, No. 2. pp. 276-303.
@article{54b1c8964a00446eb76ee0e69ad79ebd,
title = "Is the European medical products authorization regulation equipped to cope with the challenges of nanomedicines?",
abstract = "This article analyses the emerging European regulatory activities in relation to nanopharmaceuticals. The central question is whether the regulatory responses are appropriate to cope with the regulatory problems nanomedicinal development is posing. The article explores whether the medical product regulations are robust enough, whether there are certain regulatory gaps, and whether the competent bodies have the expertise to evaluate nanomedicinal products when approval is applied for. Based on a social-constructive approach, the article identifies significant regulatory actors, their ideas on regulatory problems, and preliminary governance responses to them. It finds that the current dynamic regulatory structure appears robust enough to adapt to some of the technological challenges posed by nanomedicines. It concludes that regulators have not yet responded adequately to regulatory gaps related to definitions, classification and specific safety, quality, and efficacy standards that nanopharmaceutical development seems to require. As a consequence of these deficiencies legal certainty, a principle of high priority in European medical regulation policy, cannot be sufficiently provided.",
keywords = "METIS-271225, IR-78741",
author = "Dorbeck-Jung, {Barbel R.} and Nupur Chowdhury and Nupur Chowdhury",
year = "2011",
doi = "10.1111/j.1467-9930.2011.00339.x",
language = "English",
volume = "33",
pages = "276--303",
journal = "Law & policy",
issn = "0265-8240",
publisher = "Wiley-Blackwell",
number = "2",

}

Is the European medical products authorization regulation equipped to cope with the challenges of nanomedicines? / Dorbeck-Jung, Barbel R.; Chowdhury, Nupur; Chowdhury, Nupur.

In: Law & policy, Vol. 33, No. 2, 2011, p. 276-303.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Is the European medical products authorization regulation equipped to cope with the challenges of nanomedicines?

AU - Dorbeck-Jung, Barbel R.

AU - Chowdhury, Nupur

AU - Chowdhury, Nupur

PY - 2011

Y1 - 2011

N2 - This article analyses the emerging European regulatory activities in relation to nanopharmaceuticals. The central question is whether the regulatory responses are appropriate to cope with the regulatory problems nanomedicinal development is posing. The article explores whether the medical product regulations are robust enough, whether there are certain regulatory gaps, and whether the competent bodies have the expertise to evaluate nanomedicinal products when approval is applied for. Based on a social-constructive approach, the article identifies significant regulatory actors, their ideas on regulatory problems, and preliminary governance responses to them. It finds that the current dynamic regulatory structure appears robust enough to adapt to some of the technological challenges posed by nanomedicines. It concludes that regulators have not yet responded adequately to regulatory gaps related to definitions, classification and specific safety, quality, and efficacy standards that nanopharmaceutical development seems to require. As a consequence of these deficiencies legal certainty, a principle of high priority in European medical regulation policy, cannot be sufficiently provided.

AB - This article analyses the emerging European regulatory activities in relation to nanopharmaceuticals. The central question is whether the regulatory responses are appropriate to cope with the regulatory problems nanomedicinal development is posing. The article explores whether the medical product regulations are robust enough, whether there are certain regulatory gaps, and whether the competent bodies have the expertise to evaluate nanomedicinal products when approval is applied for. Based on a social-constructive approach, the article identifies significant regulatory actors, their ideas on regulatory problems, and preliminary governance responses to them. It finds that the current dynamic regulatory structure appears robust enough to adapt to some of the technological challenges posed by nanomedicines. It concludes that regulators have not yet responded adequately to regulatory gaps related to definitions, classification and specific safety, quality, and efficacy standards that nanopharmaceutical development seems to require. As a consequence of these deficiencies legal certainty, a principle of high priority in European medical regulation policy, cannot be sufficiently provided.

KW - METIS-271225

KW - IR-78741

U2 - 10.1111/j.1467-9930.2011.00339.x

DO - 10.1111/j.1467-9930.2011.00339.x

M3 - Article

VL - 33

SP - 276

EP - 303

JO - Law & policy

JF - Law & policy

SN - 0265-8240

IS - 2

ER -